E. I. Du Pont de Nemours & Co. v. United States

471 F.2d 1211, 200 Ct. Cl. 391, 177 U.S.P.Q. (BNA) 14, 31 A.F.T.R.2d (RIA) 614, 1973 U.S. Ct. Cl. LEXIS 184
CourtUnited States Court of Claims
DecidedJanuary 18, 1973
DocketNo. 256-66 and 371-66
StatusPublished
Cited by22 cases

This text of 471 F.2d 1211 (E. I. Du Pont de Nemours & Co. v. United States) is published on Counsel Stack Legal Research, covering United States Court of Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
E. I. Du Pont de Nemours & Co. v. United States, 471 F.2d 1211, 200 Ct. Cl. 391, 177 U.S.P.Q. (BNA) 14, 31 A.F.T.R.2d (RIA) 614, 1973 U.S. Ct. Cl. LEXIS 184 (cc 1973).

Opinion

Davis, Judge,

delivered the opinion of the court:

We are narrowly concerned with only one issue on these limited cross-motions for partial summary judgment in plaintiff E. I. Du Pont de Nemours and Company’s (Du Pont) complex tax refund suits for 1959 and 1960. That question involves only one of the firm’s inter-corporate transactions, presented by a setoff defense raised by the Government against the refund claims.1 There is agreement upon the facts of this transaction, and only a legal problem — the application of section 351 of the Internal Revenue Code, 26 IT.S.O. § 351 (1970) — remains to be decided.

In 1959, Du Pont was engaged in the domestic sale and exportation (to France, among other places) of urea herbicides. Although doing the manufacturing in this country, the company owned French patents for the product. French law provided that French-patented items must be manufactured in France within three years of the issuance of the patent. If this were not done, the owner had to grant, upon request, a license to a French producer. In order to forestall that result, with its potential loss of income, Du Pont organized (in October 1959) a wholly-owned French subsidiary, Du Pont de Nemours (France) S.A., to manufacture the herbicide in France.2 By agreement in December 1959 plain[395]*395tiff granted to the subsidiary a royalty-free, non-exclusive license to make, use and sell urea herbicides under the French patents. Du Pont thereby gave up its right to assert patent infringement against the subsidiary’s products for the duration of the license, which was for the remaining life of the patents. The subsidiary had the right to sublicense manufacturing for its own needs, but any other sublicensing could only be done with the parent’s consent. In exchange for this grant, and in lieu of royalties, Du Pont received stock in the subsidiary valued at $411,500. After the award of the license, the subsidiary proceeded to arrange for manufacture of the herbicides for its own account by an unrelated French firm.

Before undertaking this arrangement, taxpayer requested rulings from the Commissioner of Internal Eevenue as to whether the proposed transaction would comply with the requirements of sections 351 and 367 of the Code. Section 351(a), as enacted in the 1954 Code and in effect in 1959, provided that:

(a) General Eule. — No gain or loss shall be recognized if property is transferred to a corporation by one or more persons solely in exchange for stock or securities in such corporation and immediately after the exchange such person or persons are in control (as defined in section 368(c)) of the corporation. For purposes of this section, stock or securities issued for services shall not be considered as issued in return for property.

Section 367 declared that, if the transaction involved transfer of property to a foreign corporation in exchange for its stock, nonrecognition would only be granted if it were established to the Commissioner’s satisfaction that the exchange were not part of a plan for the avoidance of federal income tax. The Internal Eevenue Service ruled in November 1959 that the demands of section 367 were met, but not those of section 351. It was said that “[s]ince all substantial rights of the patents will not be transferred * * * to the new French company, such patents will not be considered property within the meaning of section 351 * * Despite this holding, Du Pont proceeded with the incorporation of the subsidiary, and the grant of the non-exclusive license, but the [396]*396worth of the affiliate’s stock was not included as income in taxpayer’s 19'59 return. Since the shares received by Du Pont were valued at $411,500, and it claimed no basis in the patents, the size of the present claim by defendant for setoff is $411,500.3

There is no question, of course, that plaintiff meets the condition of section 351 that it must be in control of the subsidiary after the transaction. The controversy implicates the other prime elements of the provision: “property”, “transfer”, “exchange.” The Government has vacillated somewhat in tying the articulation of its position to one or another of those statutory terms. The 1959 ruling given to taxpayer deemed the patent rights transferred to the subsidiary not to be “property”. Conceding that this “did not adequately express the basis for the Government’s action,” the defendant now stresses the reasoning of Rev. Rui. 69-156, 1969-1 Cum. Bull. 101:

The grant of patent rights to a corporation will constitute a transfer of property within the meaning of section 351 of the Code only if the grant of these rights in a transaction which would ordinarily be taxable, would constitute a sale or exchange of property rather than a license for purposes of determining gain or loss. In order for such a grant of patent rights to * * * constitute a sale or exchange, the grant must consist of all substantial rights to the patent.

The present emphasis is thus on the “exchange” requirement, with that factor being equated with the concept of “sale or exchange” under the capital gains provisions of the Code. If a transaction does not qualify as a “sale or exchange” for those purposes, it caimot (according to the defendant) be a “transfer” of “property” “in exchange” under section 351. On that view, the Government would be entitled to its offset since it is settled that the proceeds of a grant of a simple nonexclusive patent license are not eligible for capital gains treatment. To attain that status there must normally be a transfer of an interest in all substantial rights to the patent, or of exclusive rights in a defined area. See, e.g., E. I. Du Pont [397]*397de Nemours & Co. v. United States, 153 Ct. Cl. 274, 287-88, 288 F. 2d 904, 911-12 (1961).

I.

The first and principal problem, then, is whether section 351 embodies the same notions as the capital gains provisions (26 U.S.C. §§1201 et seq. (1970)). In searching out the answer, we look to the language of the sections being compared, their individual purposes, their history and context, as well as their treatment by the courts.

Congress, it is plain, did not use identical wording. First, section 351 speaks of “property”, not of “capital assets”, and the Government concedes that section 351 can apply to property which is not a capital asset. Nonrecognition under the provision has been granted, for instance, to transfers of physical inventory (see Connolly Tool & Eng'r Co., 23 CCH Tax Ct. Mem. 1222, 1224 (1964)), of accounts receivable (see P. A. Birren & Son, Inc. v. Commissioner, 116 F. 2d 718 (C.A. 7,1940)), and of money (Halliburton v. Commissioner, 78 F. 2d 265 (C.A. 9, 1935), accepted in G.C.M. 24415, 1944 cum. bull. 219) 4 Second, the capital gains part of the Code uses “sale or exchange” of an asset (see 26 U.S.C. § 1222 (1970)), while section 351 is phrased in terms of property “transferred * * * in exchange.” This latter difference is obviously not controlling, but the fact that the drafters made the distinction in language cautions against a wholesale and automatic adoption for section 351 of the concepts of the capital gains provisions.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Principal Life Insurance v. United States
70 Fed. Cl. 144 (Federal Claims, 2006)
Coltec Industries, Inc. v. United States
62 Fed. Cl. 716 (Federal Claims, 2004)
Merck & Co. v. United States
24 Cl. Ct. 73 (Court of Claims, 1991)
Phillips Petroleum Co. v. Commissioner
97 T.C. No. 3 (U.S. Tax Court, 1991)
G.D. Searle & Co. v. Commissioner
88 T.C. No. 16 (U.S. Tax Court, 1987)
Eli Lilly & Co. v. Commissioner
84 T.C. No. 65 (U.S. Tax Court, 1985)
United States v. D.N. Stafford and Flora C. Stafford
727 F.2d 1043 (Eleventh Circuit, 1984)
Hospital Corp. of America v. Commissioner
81 T.C. No. 31 (U.S. Tax Court, 1983)
IDI Management, Inc. v. Commissioner
1977 T.C. Memo. 369 (U.S. Tax Court, 1977)
Stafford v. United States
435 F. Supp. 1036 (M.D. Georgia, 1977)
Hempt Bros., Inc. v. United States
490 F.2d 1172 (Third Circuit, 1974)

Cite This Page — Counsel Stack

Bluebook (online)
471 F.2d 1211, 200 Ct. Cl. 391, 177 U.S.P.Q. (BNA) 14, 31 A.F.T.R.2d (RIA) 614, 1973 U.S. Ct. Cl. LEXIS 184, Counsel Stack Legal Research, https://law.counselstack.com/opinion/e-i-du-pont-de-nemours-co-v-united-states-cc-1973.